TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivesto AB ( (SE:VIVE) ) has provided an update.
Vivesto AB has announced a fully secured rights issue of approximately SEK 53.8 million, subject to approval by an Extraordinary General Meeting. The capital raised will be used to complete ongoing studies with Paccal Vet and Cantrixil, repay loans, and for general corporate purposes. The company aims to finance operations into the second half of 2027 and is optimistic about attracting partners for its key projects, Paccal Vet and Cantrixil, following positive interim results.
More about Vivesto AB
Vivesto AB is a company focused on the development of veterinary and cancer treatment drugs, including Paccal Vet for dogs and Cantrixil. The company is also working on realizing value from its previously market-approved cancer drug, Apealea, through partnerships.
Average Trading Volume: 570,701
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK127.5M
See more insights into VIVE stock on TipRanks’ Stock Analysis page.